Immunoassay News and Research

RSS

Research suggests people living with HIV/AIDS may be less susceptible to SARS-CoV-2

Researchers in India have conducted a study showing that the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – was lower among people living with HIV and AIDS than among the general population.

23 Jun 2021

Scientists detect delayed and reduced antibody responses after BioNTech/Pfizer COVID-19 vaccination in older adults

Researchers at the U.S. Centers for Disease Control and Prevention (CDC) detected delayed and reduced antibody and T cell responses after immunization with BNT162b2 or the Pfizer-BioNTech COVID-19 vaccine in older adults compared with healthcare workers in Germany.

11 Jun 2021

What are the challenges of SARS-CoV-2 serosurveillance in COVID-19 vaccine recipients?

An opinion paper by researchers from the US and Italy recently discussed various aspects of monitoring anti-SARS-CoV-2 antibodies before and after receiving COVID-19 vaccination to highlight the pros and cons of this monitoring strategy. This paper is published in the open-access journal Diagnostics.

9 Jun 2021

Radiometer launches the next generation of transcutaneous monitoring in Canada

Radiometer has unveiled its Health Canada licensed TCM5 transcutaneous monitor, addressing the critical care needs of neonatal, pediatric, and adult patients, as well as sleep clinic

From Radiometer Medical 9 Jun 2021

Beckman Coulter launches new Access AMH Advanced assay to predict poor ovarian response

Beckman Coulter, a global leader in diagnostics and infertility testing, announced today the launch of the first and only test that uses a validated cut-off to aid in the assessment of ovarian response.

7 Jun 2021

Study shows CoronaVac to have high seroconversion rate after 40 days

Researchers from the Federal University of Paraná, Brazil, looked into the seroconversion rate after vaccination with the CoronaVac. Using immunoassays, they measured the immunoglobulins (IgG) for anti-nucleocapsid protein (anti-N) antibodies and anti-spike-1 (anti-S1) protein antibodies.

27 May 2021

Pirfenidone significantly reduces a marker of heart muscle scarring

Patients with heart failure with preserved ejection fraction who took the antifibrotic drug pirfenidone saw a significant reduction in a marker of heart muscle scarring compared with patients who received a placebo, based on findings from an early-phase trial presented at the American College of Cardiology's 70th Annual Scientific Session.

18 May 2021

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

To monitor antibody level duration of vaccine-induced immune responses, a team of researchers in the U.S. – at Diacarta, University of California and VA Healthcare System, and the Franciscan University of Steubenville – evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for quantitative antibody response evaluation after COVID-19 vaccination.

20 Apr 2021

Population-based study shows the persistence of neutralizing antibodies against coronavirus

It is an open question to what extent protection against reinfection persists after overcoming a SARS-CoV-2 infection.

15 Apr 2021

New study shows large within- and between-assay variation for ß-CTX measurement

A new study by the IFCC‑IOF Committee for Bone Metabolism shows large within- and between-assay variation for ß-CTX measurement; until harmonization is achieved, proposes measuring ß-CTX by the same assay on EDTA plasma, especially for research.

25 Mar 2021

Immunoassay heterogeneity and implications for SARS-CoV-2 serosurveillance

In a recent study, scientists have quantified anti-SARS-CoV-2 antibody levels up to 9 months after infection.

23 Mar 2021

A green tea compound shows anti-SARS-CoV-2 properties in vitro

Researchers show the antiviral potential of a green tea compound against SARS-CoV-2 infection.

22 Mar 2021

Saliva-based testing as a method for monitoring population immunity to SARS-CoV-2 infection

Researchers in the United States have shown that saliva-based sampling could serve as an accurate and non-invasive alternative to blood sampling for monitoring people’s antibody responses following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or vaccination against the virus.

16 Mar 2021

Preclinical study finds immune benefit in unrefrigerated Soligenix coronavirus vaccines

A new study reports positive outcomes from two new vaccine candidates. The research, led by Axel T. Lehrer from the University of Hawaii at Manoa, studied mice's immune response when administered the CoVaccine HT adjuvant with an insect-cell expressed SARS-CoV-2 spike protein ectodomain.

4 Mar 2021

Early antibody response predicts COVID-19 outcome

To address this gap, researchers from the U.S. evaluated the timing of antibody production against SARS-CoV-2 in hospitalized patients. They used a highly sensitive multiplexed bead-based immunoassay that allows for early detection of anti-SARS-CoV-2 antibodies. The study is published on the preprint server medRxiv.

2 Mar 2021

Survey reveals impact of Pfizer-BioNTech vaccination in the UK

Researchers at Imperial College London in the UK have reported on round five of the REal-time Assessment of Community Transmission-2 (REACT-2) program – a cross-sectional community survey measuring the prevalence of antibodies against the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among adults in England.

2 Mar 2021

Researchers evaluate surrogate large-scale SARS-CoV-2 serosurveillance test

A team of international scientists has recently evaluated a surrogate virus neutralization test for severe acute respiratory coronavirus 2 (SARS-CoV-2) and observed that it is highly efficacious for detecting anti-SARS-CoV-2 neutralizing antibodies in serum samples. According to the scientists, the test can be effectively used for population-level serosurveillance and evaluation of vaccine efficacy. The study is currently available on the medRxiv* preprint server.

1 Mar 2021

Immunoassay News and Research

Research suggests people living with HIV/AIDS may be less susceptible to SARS-CoV-2

Scientists detect delayed and reduced antibody responses after BioNTech/Pfizer COVID-19 vaccination in older adults

What are the challenges of SARS-CoV-2 serosurveillance in COVID-19 vaccine recipients?

Radiometer launches the next generation of transcutaneous monitoring in Canada

Beckman Coulter launches new Access AMH Advanced assay to predict poor ovarian response

Study shows CoronaVac to have high seroconversion rate after 40 days

Pirfenidone significantly reduces a marker of heart muscle scarring

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

Population-based study shows the persistence of neutralizing antibodies against coronavirus

New study shows large within- and between-assay variation for ß-CTX measurement

Immunoassay heterogeneity and implications for SARS-CoV-2 serosurveillance

A green tea compound shows anti-SARS-CoV-2 properties in vitro

Saliva-based testing as a method for monitoring population immunity to SARS-CoV-2 infection

Preclinical study finds immune benefit in unrefrigerated Soligenix coronavirus vaccines

Early antibody response predicts COVID-19 outcome

Survey reveals impact of Pfizer-BioNTech vaccination in the UK

Researchers evaluate surrogate large-scale SARS-CoV-2 serosurveillance test

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

Study shows antibody responses persisting 10 months after SARS-CoV-2 infection

Vaccinated mothers may pass on SARS-CoV-2 antibodies to newborns

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News